Drug Trial Radar · NCT00153946
Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
Last checked: Nov 20, 2026Latest source record: May 14, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
814
Actual
Start
Aug 2004
Primary completion
Mar 2008
Study completion May 2008
Sponsor
- Lead sponsor
- Combination Therapy for Acute Ischemic Stroke Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Japan Cardiovascular Research Foundation
- First posted
- Sep 12, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and have frequently been used for the treatment of acute brain infarction in Japan. The effect of combination therapy of these drugs, however, has not yet been elucidated. This study will test the safety and efficacy of the combination therapy with these agents in patients with acute non-cardioembolic and non-lacunar ischemic stroke.
Conditions
- Stroke
Interventions
EdaravoneDrug
30mg/20mL vial, twice per day, not longer than two weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Modified Rankin Scale (MRS) scoreTime frame: at 3 months
- Symptomatic intracranial hemorrhageTime frame: for the initial 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
EAST Study Office c/o National Cardiovascular Center
Suita, Osaka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.